Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Johnson and Johnson
Mallinckrodt
McKesson
Express Scripts

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Galunisertib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Galunisertib?

Galunisertib is an investigational drug.

There have been 11 clinical trials for Galunisertib. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Adenocarcinoma. The leading clinical trial sponsors are Eli Lilly and Company, Fundación para la Investigación del Hospital Clínico de Valencia, and AstraZeneca.

There are six US patents protecting this investigational drug and fifty-three international patents.

Recent Clinical Trials for Galunisertib
TitleSponsorPhase
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAgendiaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAzienda Ospedaliera Niguarda Cà GrandaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerCatalan Institute of HealthPhase 1/Phase 2

See all Galunisertib clinical trials

Clinical Trial Summary for Galunisertib

Top disease conditions for Galunisertib
Top clinical trial sponsors for Galunisertib

See all Galunisertib clinical trials

US Patents for Galunisertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Galunisertib   Start Trial Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)   Start Trial
Galunisertib   Start Trial Quinolinyl-pyrrolopyrazoles Eli Lilly and Company (Indianapolis, IN)   Start Trial
Galunisertib   Start Trial Quinolinyl-pyrrolopyrazoles Eli Lilly and Company (Indianapolis, IN)   Start Trial
Galunisertib   Start Trial TGF-.beta. inhibitors Eli Lilly and Company (Indianapolis, IN)   Start Trial
Galunisertib   Start Trial Compositions and methods for treating and preventing neointimal stenosis Yale University (New Haven, CT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Galunisertib

Drugname Country Document Number Estimated Expiration Related US Patent
Galunisertib World Intellectual Property Organization (WIPO) 2015066053 2033-10-28   Start Trial
Galunisertib Austria 341550 2022-11-22   Start Trial
Galunisertib Australia 2003291643 2022-11-22   Start Trial
Galunisertib Brazil 0315337 2022-11-22   Start Trial
Galunisertib Canada 2501322 2022-11-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Moodys
Boehringer Ingelheim
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.